PHPing He

Ping He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ping He has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Dezhi Mu

    Department of Pediatrics, West China Second University Hospital, Sichuan University, China

    1 shared publication
  • Dong Deng

    Laboratory of Epigenetics and Immunology, West China Institute of Women and Children’s Health, NHC Key Laboratory of Chronobiology, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Gaoxia Yang

    Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Guangchao Cao

    The Biomedical Translational Research Institute, Health Science Center (School of Medicine), Jinan University, Guangzhou, China

    1 shared publication
  • Jieying Gan

    Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Jiyu Tong

    Laboratory of Epigenetics and Immunology, West China Institute of Women and Children’s Health, NHC Key Laboratory of Chronobiology, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    Glioblastoma exploits ATP from leading-edge astrocytes to fuel its infiltrative growth revealed by spatially resolved chimeric analysis

    by Gaoxia Yang, Xiaodong Niu, Jieying Gan, Tianping Yu, Menghan Li, Peng Xiao, Rui Zhang, Ping He, Yuan Yang, Yi Cui, et al.

    Glioblastoma (GBM) is the deadliest primary brain tumor that frequently infiltrates surrounding brain tissue, causing therapy resistance and recurrence. The molecular characteristics of infiltrating GBM cells and their interactions with brain cells remain poorly understood, partly due to limited spatial tools for distinguishing tumor cells from those in the tumor microenvironment (TME). Here, we introduce Spatially-resolved Chimeric AnalyzeR (SCAR), a computational tool for dissecting tumor-TME gene expression in spatial transcriptomics of human-mouse chimeric cancer models. SCAR reveals spatially distinct characteristics of GBM and their interactions with TME, identifying that infiltrative GBM up-regulates creatine kinase brain type (CKB) at the astrocyte-enriched leading edge compared to the tumor core. Mechanistically, GBM-secreted CKB catalyzes the extracellular conversion of astrocyte-supplied adenosine triphosphate (ATP) and creatine into phosphocreatine, providing metabolic support for infiltrative tumor growth, which can be blocked by cyclocreatine. These results provide proof-of-concept validation of SCAR and demonstrate spatial context–dependent metabolic rewiring of GBM cells, with implications for therapies targeting infiltrative GBM.


  • DDX55 safeguards naïve T cell homeostasis by suppressing activation-promoting transposable elements

    by Mengyue Wu, Kepan Linghu, Qimin Yin, Ping He, Xinyang Yu, Peng Hu, Rongying He, Qinyun Du, Shengli Wang, Xi Chen, et al.

    Naïve T cells are maintained in a homeostatic state to preserve a stable T cell pool with diverse T cell receptor (TCR) repertoires, ensuring preparedness for priming. However, the underlying mechanisms controlling naïve T cell homeostasis and priming remain unclear. Leveraging a machine learning–based functional genetic screen, we identified DEAD-box helicase 55 ( Ddx55 ) as the top factor responsible for naïve T cell homeostasis. DDX55 was highly expressed in naïve T cells and suppressed enhancer- and promoter-like transposable elements (TEs) near T cell activation–associated genes. Ddx55 loss led to derepression of these TEs, resulting in TE-derived R loops and genomic instability, ultimately disrupting naïve T cell homeostasis and abolishing T cell proliferation. Mechanistically, DDX55-targeted TEs harbored myelocytomatosis oncogene (MYC)–binding motifs. DDX55 directly bound MYC and restricted its access to these TE loci, thereby preventing inappropriate TE activation in naïve T cells. Thus, naïve T cells exploit DDX55 as a vital regulator of T cell activation, ensuring their genomic stability and homeostatic maintenance.